Explore All 400 Growth Capital Life Science Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | May 7, 2021 |
| Target | Dejin Medical |
| Sector | Life Science |
| Investor(s) | DCP Capital |
| Deal Type | Growth Capital |
FILTER BY
DCP is a private equity firm focused on long-term partnerships with management teams in companies across Asia. The Firm seeks businesses with growth potential in a variety of industries including business services, consumer products, distribution, food, manufacturing, financial services, real estate, and staffing. DCP is headquartered in Beijing, China.
| Deal Context for Investor | # |
|---|---|
| Overall | 12 of 15 |
| Sector: Life Science | 3 of 3 |
| Type: Growth Capital | 5 of 5 |
| Country: China | 10 of 13 |
| Year: 2021 | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-04-19 |
Adopt a Cow
Beijing, China Adopt a Cow is a dairy company whose products reach consumers directly. Adopt a Cow was founded in 2016 and is based in Beijing. China. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-06-18 |
Ambrx
San Diego, California, United States Ambrx is a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety of its candidate therapeutics in multiple cancer indications, including ARX517, its proprietary ADC targeting PSMA for metastatic castration-resistant prostate cancer (mCRPC); ARX788, its proprietary ADC targeting human epidermal growth factor receptor 2 (HER2) for metastatic HER2+ breast cancer; and ARX305, its proprietary ADC targeting CD-70 for renal cell carcinoma. Ambrx was founded in 2003 and is based in San Diego, California. |
Sell | - |
